Key result
Streptococcus anginosus group endocarditis shows similar mortality and embolic event rates to VGS/SGG endocarditis.
Why the study?
Although Streptococcus anginosus group endocarditis is considered severe with abscess formation and embolic events, limited evidence supports this assumption.
Does Streptococcus anginosus group infective endocarditis have worse clinical outcomes compared to viridans group streptococci or Streptococcus gallolyticus group endocarditis?
Cohort (n=216)
Yes
Does Streptococcus anginosus group infective endocarditis have worse clinical outcomes compared to viridans group streptococci or Streptococcus gallolyticus group endocarditis?
Streptococcus anginosus group infective endocarditis has a similar prognosis and complication rate to viridans group streptococci and Streptococcus gallolyticus group endocarditis, challenging the assumption that it is a more severe disease.
Answers are grounded in this paper and cite their sources.
Questions presumed SAG endocarditis severity; cohort data vs VGS leaves open differences in abscess or embolic risk.
Background Although Streptococcus anginosus group (SAG) endocarditis is considered a severe disease associated with abscess formation and embolic events, there is limited evidence to support this assumption. Methods We performed a retrospective analysis of prospectively collected data from consecutive patients with definite SAG endocarditis in 28 centers in Spain and Italy. A comparison between cases due to SAG endocarditis and viridans group streptococci (VGS) or Streptococcus gallolyticus group (SGG) was performed in a 1:2 matched analysis. Results Of 5336 consecutive cases of definite endocarditis, 72 (1.4%) were due to SAG and matched with 144 cases due to VGS/SGG. SAG endocarditis was community acquired in 64 (88.9%) cases and affected aortic native valve in 29 (40.3%). When comparing SAG and VGS/SGG endocarditis, no significant differences were found in septic shock (8.3% vs 3.5%, P = .116); valve disorder, including perforation (22.2% vs 18.1%, P = .584), pseudoaneurysm (16.7% vs 8.3%, P = .108), or prosthesis dehiscence (1.4% vs 6.3%, P = .170); paravalvular complications, including abscess (25% vs 18.8%, P = .264) and intracardiac fistula (5.6% vs 3.5%, P = .485); heart failure (34.7% vs 38.9%, P = .655); or embolic events (41.7% vs 32.6%, P = .248). Indications for surgery (70.8% vs 70.8%; P = 1) and mortality (13.9% vs 16.7%; P = .741) were similar between groups. Conclusions SAG endocarditis is an infrequent but serious condition that presents a prognosis similar to that of VGS/SGG.
No takes yet. Share an insight, caveat, or question.
Escrihuela-Vidal et al. (2021) conducted a cohort in Infective Endocarditis (n=216). Streptococcus anginosus group (SAG) endocarditis vs. Viridans group streptococci (VGS) or Streptococcus gallolyticus group (SGG) endocarditis was evaluated on Mortality (p=.741). Streptococcus anginosus group endocarditis presented similar rates of mortality (13.9% vs 16.7%, P=0.741) and embolic events (41.7% vs 32.6%, P=0.248) compared to VGS/SGG endocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: